Genentech Avastin Launch Expected Within Three Weeks Of FDA Approval
This article was originally published in The Pink Sheet Daily
Genentech and FDA are in negotiations over final labeling and Phase IV commitments.
You may also be interested in...
The company is understood to be in talks with FDA over the optimal dose for Avastin. A delay would allow Bristol's Erbitux to enjoy at least two months on the market before facing a biologic competitor.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.